11.1 Women's Health, Contraception & Pregnancy

11.1 Women's Health, Contraception & Pregnancy

Quick Answer: For contraception and reproductive safety, match method to medical eligibility (especially VTE, smoking, age, migraine with aura, and cardiovascular risk), counsel adherence and missed-dose rules, supply emergency contraception only after structured assessment, and treat pregnancy/lactation decisions as AMH-first clinical checks — category letters are a starting frame, not a complete answer. Know classic teratogens (isotretinoin, valproate, methotrexate, ACEI/ARB) and escalate early.

Women's health appears across APC Intern Written Standards 3.1–3.3: assess patient factors, implement a safe medication plan, and monitor for adverse effects or treatment failure. Community pharmacists commonly manage combined oral contraceptives (COCs), progestogen-only methods, emergency contraception (EC), pregnancy enquiries, lactation questions, and menopausal hormone therapy (HRT) queries. Open-book resources (AMH and APF) support dosing, cautions, and counselling standards — your exam skill is recognising which risk frame applies and what counselling or referral is non-negotiable.

Combined oral contraceptives — counselling and VTE/smoking/age risks

COCs contain an oestrogen (usually ethinylestradiol) plus a progestogen. They prevent ovulation and thicken cervical mucus. Efficacy is high with perfect use but falls with missed pills, vomiting, severe diarrhoea, and interacting enzyme inducers.

Core counselling points:

• Take at the same time each day; explain the pack design (active tablets vs placebo/hormone-free interval)
• Missed-pill rules depend on how late the dose is and where in the cycle the miss occurs — use the product CMI/APF-style algorithm in practice; exam scenarios often test whether extra precautions or EC is needed after late/missed active pills
• Non-contraceptive benefits may include cycle regulation, reduced dysmenorrhoea, and acne improvement for some formulations
• Common adverse effects: breakthrough bleeding (often settles), nausea, breast tenderness, mood change; serious risks include VTE, stroke, and MI in susceptible people

VTE and cardiovascular risk is a high-yield safety theme. Oestrogen-containing contraception increases VTE risk relative to non-use, though absolute risk remains low in healthy young non-smokers. Risk rises with:

• Age (particularly approaching and over 35 years when combined with other risks)
• Smoking (especially heavy smoking)
• Obesity, prolonged immobility, personal or strong family history of VTE
• Known thrombophilia, previous VTE, active cancer, major surgery with immobilisation
• Migraine with aura (stroke risk framing for combined hormonal contraception)

Australian community practice expects you to screen medical eligibility before supply or when reviewing ongoing use: smoking status and cigarettes/day, age, blood pressure if available, migraine history (with/without aura), VTE history, liver disease, breast cancer history, and interacting medicines. Do not treat “she has been on the Pill for years” as proof of ongoing eligibility if new risks appear (e.g. new smoking, new migraine with aura, immobilising injury).

Smoking and age interact: combined hormonal contraception is generally avoided or strongly cautioned in women ≥35 years who smoke, and smoking cessation advice is part of quality care at any age. Hypertension, diabetes with vascular disease, and multiple cardiovascular risks similarly push away from oestrogen-containing methods toward progestogen-only or non-hormonal options.

Progestogen-only options

When oestrogen is unsuitable or undesired, progestogen-only contraception includes:

Progestogen-only methods generally avoid the oestrogen-related VTE risk profile of COCs, but they are not risk-free: irregular bleeding, acne or mood effects for some agents, and rare but important method-specific issues still need counselling. Efficacy still depends on correct use (especially daily POPs). For people with complex medical histories (e.g. breast cancer, unexplained vaginal bleeding), eligibility still requires careful assessment and often medical review rather than simple “switch off the COC.”

Emergency contraception — levonorgestrel and ulipristal

EC is time-critical contraception after unprotected intercourse or contraceptive failure. In Australian community pharmacy, pharmacist supply frameworks for EC emphasise assessment before supply, not automatic sale.

Assessment themes (exam-level):

• Time since unprotected intercourse (sooner is better for all methods; product windows differ)
• Possibility already pregnant (late period, positive pregnancy test)
• Regular contraception method and what failed (missed pills, condom break)
• Other medicines (enzyme inducers reduce hormonal EC effectiveness)
• Body weight/BMI considerations that may influence product choice or counselling on reduced efficacy for some regimens
• Breastfeeding status if relevant to product selection and timing advice
• Need for ongoing contraception counselling after EC

Levonorgestrel EC is widely used; single-dose regimens are standard. Counsel that it is not an abortifacient for established pregnancy, does not protect against STIs, and is less effective than ongoing methods. If vomiting occurs soon after a dose (check product-specific time window), a repeat dose may be needed.

Ulipristal acetate is another oral EC option with a different mechanism (selective progesterone receptor modulator). Timing windows and interaction considerations differ from levonorgestrel (including a longer recommended delay before restarting hormonal contraception after ulipristal in many protocols). Do not invent exact hours in the exam if unsure — reason from principles and recall that AMH/product information is the open-book source for precise windows and restarts.

After any EC supply: advise a pregnancy test if the next period is delayed or light/abnormal; discuss STI risk if indicated; offer to optimise ongoing contraception; and document assessment per local protocol.

Pregnancy — AMH categories as concepts, not magic letters

Australian practice uses pregnancy risk classifications published in resources such as the Australian Medicines Handbook (and related TGA/product information framing). Categories (classically A, B1–B3, C, D, X in Australian systems) summarise animal/human data quality and signal risk — they do not replace clinical context.

Conceptual use for the exam:

• Category A: medicines taken by large numbers of pregnant people without proven increase in malformations
• Category B subgroups: limited human data; animal data used to grade concern
• Category C: suspected or known pharmacological effects that may be harmful without necessarily being proven major teratogens in all cases
• Category D: suspected or known increase in malformations or irreversible damage — use only if benefit outweighs risk in serious disease
• Category X: high risk of permanent damage; contraindicated in pregnancy (or when pregnancy is possible without robust prevention)

Never answer “Category C means stop immediately” as a blanket rule. Some Category C medicines are used when disease control protects mother and fetus (e.g. selected antiepileptics or other essential therapy under specialist care). Conversely, a “safer-looking” letter does not license casual use without indication.

Classic teratogens and high-risk agents

Memorise pattern recognition for agents that trigger urgent action:

• Isotretinoin: major teratogen; pregnancy prevention program awareness is mandatory (effective contraception, pregnancy testing concepts, no sharing medication). Community pharmacists must not treat isotretinoin as a routine acne script without safety framing.
• Valproate: high risk of neural tube and other congenital anomalies and neurodevelopmental harm; pregnancy prevention and specialist pathways apply in people who can become pregnant.
• Methotrexate: abortifacient/teratogenic risk; contraception during and for a period after treatment (check AMH for sex-specific advice); avoid in pregnancy.
• ACE inhibitors and ARBs: fetotoxic especially in second/third trimester (renal dysgenesis, oligohydramnios, skull hypoplasia concepts); switch planning is required when pregnancy is planned or confirmed.

Other frequent pregnancy enquiries include SSRIs (balance maternal mental health vs neonatal adaptation risk), NSAIDs (avoid late pregnancy), tetracyclines (tooth/bone effects), and warfarin (switch strategies in planned pregnancy). Always route precise management through current AMH and the prescriber/obstetric team.

Lactation — high-level safe/caution patterns

Most medicines transfer into breast milk to some degree; clinical risk depends on milk/plasma ratio concepts, infant age/maturity, oral bioavailability in the infant, and dose timing. High-level patterns:

• Prefer medicines with established lactation data when a choice exists
• Time feeds to minimise peak exposure when practical (not always necessary or possible)
• Exercise caution with sedating agents, opioids, and medicines that suppress lactation
• Cytotoxics, radiopharmaceuticals, and some immunosuppressants often require specialist advice or avoidance
• “Natural” or complementary products are not automatically safe

Do not invent absolute “safe lists” under exam pressure — state the principle, name a few common community examples if well known (e.g. many beta-lactams are commonly compatible), and defer to AMH lactation monographs.

HRT — risks and benefits overview

Menopausal hormone therapy (MHT/HRT) can relieve vasomotor symptoms and prevent bone loss in selected people. Benefits are greatest when symptoms are bothersome and therapy is individualised (oestrogen-only after hysterectomy vs combined regimens when a uterus is present to protect the endometrium).

Risk themes to counsel at overview level:

• VTE and stroke risk (route matters: transdermal oestrogen may have a more favourable VTE profile than oral in many assessments)
• Breast cancer risk with longer combined therapy
• Cardiovascular risk depends on age at initiation and time since menopause (“timing hypothesis” concept)
• Contraindications broadly include undiagnosed vaginal bleeding, hormone-sensitive cancer history, active VTE, and active liver disease

Non-hormonal options (lifestyle, selected non-hormonal medicines for flushes) exist when HRT is unsuitable. Pharmacists should support shared decisions, adherence, and red-flag referral (e.g. unilateral leg swelling, chest pain, new breast changes, postmenopausal bleeding).

Putting it together for APC scenarios

1. Eligibility first for combined hormones: age, smoking, migraine with aura, VTE, BP, interacting drugs
2. Method fit: adherence reality, bleeding tolerance, desire for LARC
3. EC: time window, interactions, pregnancy exclusion, ongoing plan
4. Pregnancy/lactation: AMH concepts + known teratogens + escalate
5. HRT: symptom benefit vs VTE/breast/CV risk, regimen type, monitoring red flags

Document advice, use open-book resources for precise numbers, and never let category letters replace clinical thinking.